Text Size

Safety and Feasibility Study of the Shockwave System to Treat Vascular Disease

This study is not yet open for participant recruitment.
Verified April 2012 by Shockwave Medical, Inc.
Sponsor:
Information provided by (Responsible Party):
Shockwave Medical, Inc.
ClinicalTrials.gov Identifier:
NCT01577888
First received: April 11, 2012
Last updated: April 13, 2012
Last verified: April 2012
History of Changes
  Purpose

To study the early safety and performance of the Shockwave Medical System in subjects to demonstrate that the device can safely and effectively deliver localized energy for the treatment of vascular disease.


Condition Intervention
Vascular Disease
 Device: Shockwave System Treatment

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Shockwave Medical, Inc.:

Primary Outcome Measures:
  • Safety determined by 30day New-Onset Serious Adverse Events [ Time Frame: 30 day ] [ Designated as safety issue: Yes ]
    New Onset Serious Adverse Events (SAE) include death, device-related surgery or repeat hospitalization, occlusion, or major unplanned amputation through 30 days following the procedure.


Secondary Outcome Measures:
  • Angiographic Success as measured by residual stenosis <30% reference vessel. [ Time Frame: Peri-Procedural ] [ Designated as safety issue: No ]

Estimated Enrollment: 10
Study Start Date: June 2012
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: treatment Device: Shockwave System Treatment
Treatment with the Shockwave Medical device during vascular disease intervention.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age >18
  • Patient or patient's legal representative have been informed of the nature of the study, agrees to participate and has signed the approved consent form.
  • Female subjects of childbearing potential have a negative pregnancy test less than 7 days before the procedure.
  • Patient is able and willing to comply with all assessments in the study.
  • Peripheral arterial disease of Rutherford Category 2, 3, 4, and 5.
  • Ability to tolerate an antiplatelet agent (i.e. aspirin, clopidigrel or prasagrel).
  • Meets Angiographic Inclusion Criteria

Exclusion Criteria:

  • Patients with peripheral arterial disease of Rutherford Category 6.
  • Severe or infected gangrene of the lower extremity.
  • Planned major amputation.
  • Previously implanted stent at the treatment site.
  • Patient with an externally-connected intracardiac catheter or pacemaker.
  • Patient with an implantable pacemaker or defibrillator.
  • Patient has connective tissue disease (e.g., Marfan's syndrome).
  • Patient has a hypercoagulable disorder.
  • Patient has allergy to imaging contrast media for which they cannot be premedicated.
  • Patient is in acute renal failure or chronic renal insufficiency or failure as measured by a serum creatinine of >19.5 µmol/L.
  • Patient has active systemic infection.
  • Patient has less than a one year life expectancy.
  • Patient is pregnant or nursing.
  • Patient is participating in another research study involving an investigational agent that has not reached the primary endpoint.
  • Patient has other medical, social or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment, and the procedures and evaluations pre- and post-treatment.
  • Chronic total occlusion of target vessel.
  • Chronic total occlusion of inflow vessel.
  • Highly tortuous arteries (bends greater than 30 degrees over the arc length of the balloon)
  • Patients requiring concurrent intervention below the most distal target lesion.
  • Inflow disease: Stenosis of >50% in vessel proximal to the target lesion which requires treatment with Drug Eluting Balloon (DEB) or atherectomy.
  • Prior procedure in target leg within past 3 months.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01577888

Locations
New Zealand
Auckland City Hospital
Auckland, New Zealand, 92024
Sponsors and Collaborators
Shockwave Medical, Inc.
  More Information

No publications provided

Responsible Party: Shockwave Medical, Inc.
ClinicalTrials.gov Identifier: NCT01577888     History of Changes
Other Study ID Numbers: SW-0047
Study First Received: April 11, 2012
Last Updated: April 13, 2012
Health Authority: New Zealand: Health and Disability Ethics Committees

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on May 16, 2013